Intuniv

Guanfacine, the active ingredient in Intuniv, is a Alpha-2A adrenergic agonist presented as an extended-release tablet for oral use. It treats attention deficit hyperactivity disorder in children and adolescents and hypertension in adults.

GNH USA supplies Intuniv as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intuniv acts on central adrenergic pathways to manage neurobehavioral and cardiovascular conditions.

- Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in pediatric patients. - Hypertension: lowers systolic and diastolic blood pressure in adult patients.

Intuniv may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Dizziness - Fatigue - Dry mouth - Headache - Insomnia - Nausea

Serious or Rare Side Effects: - Hypotension - Bradycardia - Syncope - Depression or suicidal thoughts - Severe allergic reactions - Cardiac arrhythmias

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: assess baseline and periodically during treatment. - Cardiac function: evaluate heart rate and ECG in patients with known cardiac disease. - Dose adjustments: use caution in hepatic impairment. - Concomitant CNS depressants: monitor for additive sedation. - Store at room temperature: keep in the original container, protect from moisture and light.

Guanfacine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors: may increase guanfacine plasma concentrations. - Other antihypertensives: additive hypotensive effect. - Clonidine: risk of severe hypotension when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce guanfacine levels. - Sedatives: increased drowsiness. - Alcohol: enhanced central nervous system depression.